Clinical observation of compound Kushen injection combined with XELOX chemotherapy regimen in the treatment of advanced colorectal cancer
Objective To explore the clinical efficacy and safety of compound Kushen injection (CKI)combined with XELOX chemotherapy in the treatment of advanced colorectal cancer (CRC).Methods A total of 84 patients with advanced CRC in the Sixth Hospital of Wuhan,Affiliated Hospital of Jianghan University from January 2020 to January 2023 were selected,and were divided into control group (40 cases) and experimental group (44 cases) according to different treatment methods.The control group was treated with XELOX regimen (oxaliplatin+capecitabine) chemotherapy,and the experimental group was treated with CKI on the basis of the control group for six months.The short-term efficacy index,tumor marker level,immune function level and occurrence of adverse reactions were compared between the two groups.Results Among 84 patients,there were 54 males and 30 females,aged from 36 to 87 years,with an average age of (64.1±8.6) years.The levels of partial reponse (70.5% vs.42.5%),overall response rate (70.5% vs.42.5%),CD4+[(46.7±2.8)/μl vs.(44.3±3.9)/μl]and CD4+/CD8+[(1.3±0.1) vs.(1.2±0.1)]in experimental groups were higher after treatment than those in the control group,the level of stable disease (18.2% vs.42.5%) was lower than that in the control group.Carbohydrate antigen level in the experimental group after treatment was lower than that before treatment[47.1(22.8,85.9)ng/ml vs.75.1(25.4,117.8)ng/ml],carbohydrate antigen 19-9 of two groups after treatment[165.9(86.3,285.8)U/ml vs.250.1(98.4,434.6)U/ml,144.9(78.4,265.6)U/ml vs.190.0(85.8,258.6)U/ml]、CD3+[(45.31±3.42)/μl vs.(51.7±8.6)/μl,(45.2±3.4)/μl vs.(52.1±8.8)/μl]、CD4+[(46.7±2.8)/μl vs.(53.1±2.7)/μl,(44.3±3.9)/μl vs.(53.5±2.7)/μl],CD4+/CD8+[(1.3±0.1) vs.(1.4±0.1),(1.2±0.1) vs.(1.5±0.1)]were lower than those before treatment,and the differences were statistically significant (P<0.05).Conclusions CKI combined with XELOX chemotherapy can improve the clinical efficacy of patients with advanced CRC,reduce the level of tumor markers and improve immune function.
compound kushen injection (CKI)XELOX chemotherapyadvanced colorectal cancer (CRC)tumor treatment effecttumor markersimmune function
万方数据
维普
